Zobrazeno 1 - 10 of 2 154 pro vyhledávání: '"le Bourhis X"'
1
Akademický článek
ProNGF promotes brain metastasis through TrkA/EphA2 induced Src activation in triple negative breast cancer cells.
Autor: Cicero J; UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, Boulevard du Professeur Jules Leclercq, 59000, Lille, France.; Laboratoire de La Barrière Hémato-Encéphalique (LBHE), University of Artois, UR 2465, F-62300, Lens, France.; GdR2082 APPICOM- « Approche Intégrative Pour Une Compréhension Multi-Échelles de La Fonction Des Protéines Membranaires », Paris, France., Trouvilliez S; UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, Boulevard du Professeur Jules Leclercq, 59000, Lille, France.; GdR2082 APPICOM- « Approche Intégrative Pour Une Compréhension Multi-Échelles de La Fonction Des Protéines Membranaires », Paris, France., Palma M; UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, Boulevard du Professeur Jules Leclercq, 59000, Lille, France.; GdR2082 APPICOM- « Approche Intégrative Pour Une Compréhension Multi-Échelles de La Fonction Des Protéines Membranaires », Paris, France., Ternier G; UMR-S1172, University of Lille, Inserm, CHU Lille, Équipe Développement et Plasticité du cerveau neuroendocrine, Lille Neuroscience et Cognition, 1 Place de Verdun, 59000, Lille Cedex, France., Decoster L; UMR-S1172, University of Lille, Inserm, CHU Lille, Équipe Développement et Plasticité du cerveau neuroendocrine, Lille Neuroscience et Cognition, 1 Place de Verdun, 59000, Lille Cedex, France., Happernegg E; UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, Boulevard du Professeur Jules Leclercq, 59000, Lille, France.; Laboratoire de La Barrière Hémato-Encéphalique (LBHE), University of Artois, UR 2465, F-62300, Lens, France.; GdR2082 APPICOM- « Approche Intégrative Pour Une Compréhension Multi-Échelles de La Fonction Des Protéines Membranaires », Paris, France., Barois N; University of Lille, CNRS, CHU Lille, Institut Pasteur de Lille, US 41 - UAR 2014 - PLBS, 59000, Lille, Inserm, France., Van Outryve A; UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, Boulevard du Professeur Jules Leclercq, 59000, Lille, France.; GdR2082 APPICOM- « Approche Intégrative Pour Une Compréhension Multi-Échelles de La Fonction Des Protéines Membranaires », Paris, France.; UMR 8520 -IEMN - Institut d'Electronique de Microélectronique et de Nanotechnologie, University of Lille, CNRS, Centrale Lille, Junia, University Polytechnique Hauts-de-France, 59000, Lille, France., Dehouck L; Laboratoire de La Barrière Hémato-Encéphalique (LBHE), University of Artois, UR 2465, F-62300, Lens, France., Bourette RP; UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, Boulevard du Professeur Jules Leclercq, 59000, Lille, France., Adriaenssens E; UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, Boulevard du Professeur Jules Leclercq, 59000, Lille, France., Lagadec C; UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, Boulevard du Professeur Jules Leclercq, 59000, Lille, France.; GdR2082 APPICOM- « Approche Intégrative Pour Une Compréhension Multi-Échelles de La Fonction Des Protéines Membranaires », Paris, France., Tarhan CM; UMR 8520 -IEMN - Institut d'Electronique de Microélectronique et de Nanotechnologie, University of Lille, CNRS, Centrale Lille, Junia, University Polytechnique Hauts-de-France, 59000, Lille, France.; LIMMS/CNRS-IIS IRL2820, The University of Tokyo, Tokyo, Japan., Collard D; LIMMS/CNRS-IIS IRL2820, The University of Tokyo, Tokyo, Japan.; CNRS, IIS, University of Lille SMMiL-E Project, 59000, Lille, COL, France., Souguir Z; HCS Pharma, 59120, Loos, France., Vandenhaute E; HCS Pharma, 59120, Loos, France., Maubon G; HCS Pharma, 59120, Loos, France., Sipieter F; Université Paris Cité, Centre National de La Recherche Scientifique (CNRS), Institut Jacques Monod, 15 rue Hélène Brion, 75013, Paris, France., Borghi N; Université Paris Cité, Centre National de La Recherche Scientifique (CNRS), Institut Jacques Monod, 15 rue Hélène Brion, 75013, Paris, France., Shimizu F; Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Ube, Japan., Kanda T; Department of Neurology and Clinical Neuroscience, Yamaguchi University Graduate School of Medicine, Ube, Japan., Giacobini P; UMR-S1172, University of Lille, Inserm, CHU Lille, Équipe Développement et Plasticité du cerveau neuroendocrine, Lille Neuroscience et Cognition, 1 Place de Verdun, 59000, Lille Cedex, France., Gosselet F; Laboratoire de La Barrière Hémato-Encéphalique (LBHE), University of Artois, UR 2465, F-62300, Lens, France., Maubon N; HCS Pharma, 59120, Loos, France., Le Bourhis X; UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, Boulevard du Professeur Jules Leclercq, 59000, Lille, France., Van Seuningen I; UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, Boulevard du Professeur Jules Leclercq, 59000, Lille, France., Mysiorek C; Laboratoire de La Barrière Hémato-Encéphalique (LBHE), University of Artois, UR 2465, F-62300, Lens, France., Toillon RA; UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, Boulevard du Professeur Jules Leclercq, 59000, Lille, France. robert-alain.toillon@univ-lille.fr.; GdR2082 APPICOM- « Approche Intégrative Pour Une Compréhension Multi-Échelles de La Fonction Des Protéines Membranaires », Paris, France. robert-alain.toillon@univ-lille.fr.
Publikováno v: Experimental hematology & oncology [Exp Hematol Oncol] 2023 Dec 10; Vol. 12 (1), pp. 104. Date of Electronic Publication: 2023 Dec 10.
Zobrazit plný text záznamu
2
Akademický článek
Mitochondrial adaptation decreases drug sensitivity of persistent triple negative breast cancer cells surviving combinatory and sequential chemotherapy.
Autor: Winter M; UMR9020-U1277-CANTHER-Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France., Nait Eldjoudi A; UMR9020-U1277-CANTHER-Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France., Guette C; ICO, Inserm, CNRS, Nantes Université, CRCI2NA, Université d'Angers, Angers, France., Hondermarck H; School of Biomedical Sciences and Pharmacy, College of Health, Medicine and Wellbeing, University of Newcastle, Callaghan, NSW2308, Australia; Hunter Medical Research Institute, University of Newcastle, New Lambton Heights, NSW2305, Australia., Bourette RP; UMR9020-U1277-CANTHER-Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France., Fovez Q; UMR9020-U1277-CANTHER-Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France., Laine W; UMR9020-U1277-CANTHER-Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France., Ghesquiere B; Metabolomics Expertise Center, Center for Cancer Biology, CCB-VIB, VIB, Leuven, 3000, Belgium; Metabolomics Expertise Center, Department of Oncology, KU Leuven, Leuven, 3000, Belgium., Adriaenssens E; UMR9020-U1277-CANTHER-Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France., Kluza J; UMR9020-U1277-CANTHER-Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France., Le Bourhis X; UMR9020-U1277-CANTHER-Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France. Electronic address: xuefen.le-bourhis@univ-lille.fr.
Publikováno v: Neoplasia (New York, N.Y.) [Neoplasia] 2023 Dec; Vol. 46, pp. 100949. Date of Electronic Publication: 2023 Nov 11.
Zobrazit plný text záznamu
3
Akademický článek
Influence of EGF and pro-NGF on EGFR/SORTILIN interaction and clinical impact in head and neck squamous cell carcinoma.
Autor: Morisse M; Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Center (CHU) de Lille, University of Lille, Lille, France.; Univ. Lille, Inserm, University Hospital Center (CHU) Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France., Bourhis T; Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Center (CHU) de Lille, University of Lille, Lille, France.; Univ. Lille, Inserm, University Hospital Center (CHU) Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France., Lévêque R; Univ. Lille, Inserm, University Hospital Center (CHU) Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France., Guilbert M; Univ. Lille, Inserm, University Hospital Center (CHU) Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France., Cicero J; Univ. Lille, Inserm, University Hospital Center (CHU) Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France., Palma M; Univ. Lille, Inserm, University Hospital Center (CHU) Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France., Chevalier D; Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Center (CHU) de Lille, University of Lille, Lille, France.; Univ. Lille, Inserm, University Hospital Center (CHU) Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France., le Bourhis X; Univ. Lille, Inserm, University Hospital Center (CHU) Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France., Toillon RA; Univ. Lille, Inserm, University Hospital Center (CHU) Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France., Mouawad F; Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Center (CHU) de Lille, University of Lille, Lille, France.; Univ. Lille, Inserm, University Hospital Center (CHU) Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Lille, France.
Publikováno v: Frontiers in oncology [Front Oncol] 2023 Jul 27; Vol. 13, pp. 661775. Date of Electronic Publication: 2023 Jul 27 (Print Publication: 2023).
Zobrazit plný text záznamu
4
Evofosfamide Is Effective against Pediatric Aggressive Glioma Cell Lines in Hypoxic Conditions and Potentiates the Effect of Cytotoxic Chemotherapy and Ionizing Radiations
Autor: Bailleul Q, Navarin P, Arcicasa M, Bal-Mahieu C, Carcaboso AM, Le Bourhis X, Furlan A, Meignan S, Leblond P
Publikováno v: Cancers
r-FSJD. Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Universidad de Alicante (UA)
r-FSJD: Repositorio Institucional de Producción Científica de la Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
Simple Summary Despite many therapeutic approaches attempted over the last years, the prognosis of children with high-grade glioma or diffuse intrinsic pontine glioma remains dismal. Hypoxia-activated prodrugs (HAPs) were developed to target hypoxic
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::4e52f9f723f8143213b0cd81db296756
http://fundanet.fsjd.org/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=19597
Zobrazit plný text záznamu
5
Akademický článek
The Contribution of the Zebrafish Model to the Understanding of Polycomb Repression in Vertebrates.
Autor: Hanot M; Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France., Raby L; Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France., Völkel P; Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France., Le Bourhis X; Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France., Angrand PO; Univ. Lille, CNRS, Inserm, CHU Lille, UMR9020-U1277-CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France.
Publikováno v: International journal of molecular sciences [Int J Mol Sci] 2023 Jan 24; Vol. 24 (3). Date of Electronic Publication: 2023 Jan 24.
Zobrazit plný text záznamu
6
Akademický článek
ABSP: an automated R tool to efficiently analyze region-specific CpG methylation from bisulfite sequencing PCR.
Autor: Denoulet M; CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, University of Lille, Lille F-59000, France.; Institut pour la Recherche sur le Cancer de Lille (IRCL), Lille F-59000, France., Brulé M; CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, University of Lille, Lille F-59000, France.; Institut pour la Recherche sur le Cancer de Lille (IRCL), Lille F-59000, France., Anquez F; CNRS, UMR 8523 - PhLAM-Physique des Lasers Atomes et Molécules, University of Lille, Lille F-59000, France., Vincent A; CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, University of Lille, Lille F-59000, France., Schnipper J; Laboratory of Cellular and Molecular Physiology, UR UPJV 4667, University of Picardie Jules Verne, Amiens 80000, France., Adriaenssens E; CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, University of Lille, Lille F-59000, France., Toillon RA; CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, University of Lille, Lille F-59000, France., Le Bourhis X; CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, University of Lille, Lille F-59000, France., Lagadec C; CNRS, Inserm, CHU Lille, UMR9020-U1277 - CANTHER-Cancer Heterogeneity Plasticity and Resistance to Therapies, University of Lille, Lille F-59000, France.; Institut pour la Recherche sur le Cancer de Lille (IRCL), Lille F-59000, France.
Publikováno v: Bioinformatics (Oxford, England) [Bioinformatics] 2023 Jan 01; Vol. 39 (1).
Zobrazit plný text záznamu
7
Akademický článek
Macrophage-Colony-Stimulating Factor Receptor Enhances Prostate Cancer Cell Growth and Aggressiveness In Vitro and In Vivo and Increases Osteopontin Expression.
Autor: Mougel A; University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France., Adriaenssens E; University of Lille, CNRS, Inserm, CHU Lille, UMR9020-UMR1277-CANTHER-Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, France., Guyot B; Centre de Recherche en Cancérologie de Lyon, Department of Cancer Initiation and Tumor Cell Identity CNRS UMR5286, Inserm U1052, Lyon 1 University, F-69000 Lyon, France., Tian L; University of Lille, CNRS, Inserm, CHU Lille, UMR9020-UMR1277-CANTHER-Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, France., Gobert S; University of Lyon, Universiteé Claude Bernard Lyon 1, CNRS UMR-5305, Laboratoire de Biologie Tissulaire et Ingeénierie Theérapeutique, F-69367 Lyon, France., Chassat T; Institut Pasteur de Lille-PLEHTA (Plateforme d'Expérimentation et de Haute Technologie Animale), F-59019 Lille, France., Persoons P; Institut Pasteur de Lille-PLEHTA (Plateforme d'Expérimentation et de Haute Technologie Animale), F-59019 Lille, France., Hannebique D; Institut Pasteur de Lille-PLEHTA (Plateforme d'Expérimentation et de Haute Technologie Animale), F-59019 Lille, France., Bauderlique-Le Roy H; CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, US41-UMS 2014-PLBS, University of Lille, F-59000 Lille, France., Vicogne J; University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, U1019-UMR 9017-CIIL-Center for Infection and Immunity of Lille, F-59000 Lille, France., Le Bourhis X; University of Lille, CNRS, Inserm, CHU Lille, UMR9020-UMR1277-CANTHER-Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, France., Bourette RP; University of Lille, CNRS, Inserm, CHU Lille, UMR9020-UMR1277-CANTHER-Cancer Heterogeneity, Plasticity and Resistance to Therapies, F-59000 Lille, France.
Publikováno v: International journal of molecular sciences [Int J Mol Sci] 2022 Dec 16; Vol. 23 (24). Date of Electronic Publication: 2022 Dec 16.
Zobrazit plný text záznamu
9
Akademický článek
Direct interaction of TrkA/CD44v3 is essential for NGF-promoted aggressiveness of breast cancer cells.
Autor: Trouvilliez S; University Lille, CNRS, INSERM, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., Cicero J; University Lille, CNRS, INSERM, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France.; University Artois, UR 2465, Laboratoire de la Barrière Hémato-Encéphalique (LBHE), F-62300, Lens, France., Lévêque R; University Lille, CNRS, INSERM, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., Aubert L; University Lille, CNRS, INSERM, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., Corbet C; University Lille, CNRS, INSERM, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., Van Outryve A; University Lille, CNRS, INSERM, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., Streule K; Karlsruhe Institute of Technology, Institute of Toxicology and Genetics, 76344, Eggenstein-Leopoldshafen, Germany., Angrand PO; University Lille, CNRS, INSERM, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., Völkel P; University Lille, CNRS, INSERM, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., Magnez R; University Lille, CNRS, INSERM, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., Brysbaert G; University Lille, CNRS, UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, F-59000, Lille, France., Mysiorek C; University Artois, UR 2465, Laboratoire de la Barrière Hémato-Encéphalique (LBHE), F-62300, Lens, France., Gosselet F; University Artois, UR 2465, Laboratoire de la Barrière Hémato-Encéphalique (LBHE), F-62300, Lens, France., Bourette R; University Lille, CNRS, INSERM, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., Adriaenssens E; University Lille, CNRS, INSERM, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., Thuru X; University Lille, CNRS, INSERM, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., Lagadec C; University Lille, CNRS, INSERM, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., de Ruyck J; University Lille, CNRS, UMR 8576 - UGSF - Unité de Glycobiologie Structurale et Fonctionnelle, F-59000, Lille, France., Orian-Rousseau V; Karlsruhe Institute of Technology, Institute of Toxicology and Genetics, 76344, Eggenstein-Leopoldshafen, Germany., Le Bourhis X; University Lille, CNRS, INSERM, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France., Toillon RA; University Lille, CNRS, INSERM, CHU Lille, UMR9020-U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000, Lille, France. robert-alain.toillon@univ-lille.fr.; Université de Lille, Faculté des Sciences et Technologies, UMR CNRS 9020- INSERM U1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, Bâtiment SN3, 3ème étage, Cité scientifique, 59655, Villeneuve d'Ascq, France. robert-alain.toillon@univ-lille.fr.
Publikováno v: Journal of experimental & clinical cancer research : CR [J Exp Clin Cancer Res] 2022 Mar 28; Vol. 41 (1), pp. 110. Date of Electronic Publication: 2022 Mar 28.
Zobrazit plný text záznamu
10
Akademický článek
Loss of Polycomb Repressive Complex 2 Function Alters Digestive Organ Homeostasis and Neuronal Differentiation in Zebrafish.
Autor: Raby L; Univ. Lille, CNRS, Inserm, CHU Lille, UMR 9020-U 1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France., Völkel P; Univ. Lille, CNRS, Inserm, CHU Lille, UMR 9020-U 1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France., Hasanpour S; Department of Fisheries and Animal Sciences, Faculty of Natural Resources, University of Tehran, Karaj 31587-77871, Iran., Cicero J; Univ. Lille, CNRS, Inserm, CHU Lille, UMR 9020-U 1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France.; Univ. Artois, UR 2465, Laboratoire de la Barrière Hémato-Encéphalique (LBHE), F-62300 Lens, France., Toillon RA; Univ. Lille, CNRS, Inserm, CHU Lille, UMR 9020-U 1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France., Adriaenssens E; Univ. Lille, CNRS, Inserm, CHU Lille, UMR 9020-U 1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France., Van Seuningen I; Univ. Lille, CNRS, Inserm, CHU Lille, UMR 9020-U 1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France., Le Bourhis X; Univ. Lille, CNRS, Inserm, CHU Lille, UMR 9020-U 1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France., Angrand PO; Univ. Lille, CNRS, Inserm, CHU Lille, UMR 9020-U 1277 - CANTHER - Cancer Heterogeneity Plasticity and Resistance to Therapies, F-59000 Lille, France.
Publikováno v: Cells [Cells] 2021 Nov 12; Vol. 10 (11). Date of Electronic Publication: 2021 Nov 12.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje